Comparison of the Management of Post-prandial Hyperglycemia by Multiple Bolus Calculators
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ulm, Germany, 89081
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects >/= 18 years at screening
- Type 1 diabetics currently using an insulin pump for management of their diabetes and have been on a pump for at least at least 6 months prior to the screening visit
- Subjects have to use a fast acting analog insulin
- HbA1c = 9% (measured with DCA 2000)
- Willing to perform periods of intensive blood glucose (BG) monitoring for up to 21 days prior to the study (~10 tests per day) with skipped meals and testmeals
- Willing to use the 3 different bolus calculators during the course of the study
- Willing to undergo planned hyperglycemia
- Willing to perform high frequency BG monitoring (> 20 / day) during the experiment
Exclusion Criteria:
- Type 2 Diabetes
- Manifest severe late complications of diabetes (e.g. severe macro- or microangiopathy, severe neuropathy, severe retinopathy and/or severe nephropathy)
- Current addiction to alcohol or substances of abuse
- Pregnant or lactating women
- Any known life-threatening disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Single Arm
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To compare the difference between the self-monitoring blood glucose (SMBG) value achieved at 6 hours after meals with induced post-prandial hyperglycemia and the mean target value of 110 mg/dL. Target post-prandial range is 80-140 mg/dL.
Time Frame: 6 hours after meal
|
6 hours after meal
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To compare the absolute difference between the SMBG value and the target value between the calculators
Time Frame: 6 hours after meal
|
6 hours after meal
|
|
To compare theto compare the relative difference (multiplied by 100) between the SMBG value and the target value between the calculators
Time Frame: 6 hours after meal
|
6 hours after meal
|
|
To compare the absolute relative difference (RAD, multiplied by 100) between the SMBG value and the target value between the calculators
Time Frame: 6 hours after meal
|
6 hours after meal
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bettina Petersen, Roche Diagnostics GmbH / Diabetes Care
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RD000811
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus Type 1
-
NCT06783309RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)
-
NCT07427134RecruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes Mellitus
-
NCT06676566Enrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 Diabetes
-
NCT07336459Active, not recruitingType 2 Diabetes Mellitus 1
-
NCT03211858CompletedType 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
-
NCT05168657CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1
-
NCT07493122Not yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
NCT07610213Not yet recruitingType 1 Diabetes Mellitus | Autoimmune Diabetes | Type 1 Diabetes Mellitus (T1DM)
-
NCT01781975CompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDM
-
NCT00229658CompletedType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus
Clinical Trials on Accu-Chek Combo Kit mg DE/de
-
NCT02555306Completed
-
NCT07078331Active, not recruitingRidge Augmentation | Bone Graft | Tooth Extraction Site Healing
-
NCT03185481TerminatedParkinson's Disease With Motor Fluctuations
-
NCT01767532CompletedInfections, Respiratory Tract
-
NCT01767571CompletedInfections, Respiratory Tract
-
NCT06275243Completed
-
NCT02490085Completed
-
NCT03211234Completed